




Identify Partners Series

WORLD'S LARGEST INTELLIGENCE RESOURCE ON I/O STARTUPS

# Immuno-Oncology Startups 2020

KEY TECHNOLOGIES, PIPELINE, DEALS AND FUNDING ANALYSIS

“TOP 400  
DRUG  
DEVELOPERS  
ESTABLISHED  
BETWEEN 2010-19”



Drug Discovery Startups

***IDENTIFY PARTNERS SERIES -***

# **IMMUNOONCOLOGY STARTUPS 2020**

**WORLD'S LARGEST RESOURCE ON IMMUNOONCOLOGY DRUG DEVELOPING STARTUPS**

**QUANTITATIVE & QUALITATIVE ANALYSIS OF TOP 400 STARTUPS ESTABLISHED BETWEEN 2010-2019**

# Disclaimer

At the time of creation of this report, all information present herein was known to be true and accurate, to the best knowledge of creators. HH BioTechnologies accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions affecting any part of the publication. All information is provided without warranty, and HH BioTechnologies makes no representation of warranty of any kind as to the accuracy or completeness of any information here to contained.



ISBN 978-81-926399-0-4

© December 2019 by HH BioTechnologies Pvt. Ltd. All rights reserved.

All information contained in this publication is copyrighted in the name of HH BioTechnologies Pvt. Ltd., and no part of this publication may be reproduced, resold, redistributed, stored in a retrieval system, or transmitted in any form or by any means—electronic, mechanical, photocopying, scanning, or otherwise—without prior written permission of the publisher.

Permissions may be sought directly from HH Biotechnologies' through an email at [reports@omicsx.com](mailto:reports@omicsx.com)



## TABLE OF CONTENTS

<i>Executive Summary</i> .....	<b>4</b>
<i>List of Figures</i> .....	<b>9</b>
<i>List of Tables</i> .....	<b>9</b>
<i>List of Top 400 Immuno Oncology Startup</i> .....	<b>10</b>

## **Section A : Immuno-Oncology Startups 2020** **15**

### **Top 400 Active Drug Developers' Summary**

- *Infographics - Quantitative Estimation of Immuno Oncology Startups present in U.S.A vs. Europe vs. Asia vs. Canada vs. Rest of the World. (established between Jan 2010 to July 2019).*
- *Infographics - Distribution of Top 400 Immuno Oncology Startups, on the basis of Year of Establishment.*  
To explore the emergence of Cancer Drug Discovery And Development.
- *Infographics - Country-wise Distribution of Immuno Oncology Startups having Active Cancer Drug Development Program in Europe & Asia Region.*  
To identify best and emerging countries, for promoting cancer startups.
- *Infographics - State-wise Distribution of Immuno Oncology Startups having Active Cancer Drug Development Program in U.S.A.*  
To explore the Top cancer startups supporting States in United States.

- ***Top 15 Innovative Game Changer Immuno-Oncology Startups.***  
Capable of changing tomorrow's Cancer Drug Discovery & Development.
- ***Immuno-Oncology Startups Developing - Immune Checkpoint Modulators.***  
Developing drugs, which blocks certain proteins (PD-1/PD-L1 and CTLA-4/B7-1/B7-2), made by some types of immune system cells, such as T cells, and some cancer cells. **(43 Companies)**
- ***Immuno-Oncology Startups Developing - Cellular Immunotherapies.***  
Developing Chimeric Antigen Receptor (CAR) T-cell therapy, T-cell Receptor (TCR) therapy, Tumor-Infiltrating Lymphocytes (TIL) therapy, Dendritic Cell Vaccine. **(98 Companies)**
- ***Immuno-Oncology Startups Developing - Oncolytic Viruses based Therapeutics.***  
Non-pathogenic viral strains which selectively infect and kill malignant cells, while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. **(33 Companies)**
- ***Immuno-Oncology Startups Developing - Peptide Vaccines.***  
Stimulating immune response against one or multiple Tumor-Associated Antigens following immunization with purified, recombinant or synthetically engineered epitopes. **(27 Companies)**
- ***Immuno-Oncology Startups Developing - Bispecific T Cell Engagers.***  
Bispecific molecules redirecting the cytotoxicity of T-cells Tumor-Associated Antigens following immunization with purified, recombinant or synthetically engineered epitopes. **(13 Companies)**
- ***Immuno-Oncology Startups Developing- Monoclonal Antibodies against Tumor Antigen.***  
**(93 Companies)**

## Section B : Venture Funding & Big Pharma Partnering - I/O Startups 2020 **33**

### Big Pharma Partnering, Deals & Investments in Startups

- ***Immuno-Oncology Startups - MAJOR DEALS & PARTNERING ACTIVITIES - 2019***  
**(uptill Nov. 2019)**  
**(54 I/O Exclusive Deals Details)**
- ***Immuno-Oncology Startups - MAJOR DEALS & PARTNERING ACTIVITIES - 2018***  
**(62 I/O Exclusive Deals Details)**
- ***Immuno-Oncology Startups - MAJOR DEALS & PARTNERING ACTIVITIES - 2017***  
**(54 I/O Exclusive Deals Details)**

## Venture Funding Investment Deals in I/O Startups

- ***Immuno-Oncology Startups Funding - 2019 (uptill Nov 2019)***  
Amount Raised; Funding Details - Seed, Series A, Series B, Series C, Grants and Initial Public Offering; Investors Details, etc. **(60 I/O Exclusive Funding Details)**
- ***Immuno-Oncology Startups Funding - 2018***  
Amount Raised; Funding Details - Seed, Series A, Series B, Series C, Grants and Initial Public Offering; Investors Details, etc. **(99 I/O Exclusive Funding Details)**
- ***Immuno-Oncology Startups Funding - 2017***  
Amount Raised; Funding Details - Seed, Series A, Series B, Series C, Grants and Initial Public Offering; Investors Details, etc. **(89 I/O Exclusive Funding Details)**
- ***Big Pharma Investments / Partnering Deals with Immuno-Oncology Startups.***
- ***Top 10 Venture Investors, and their Active Immuno-Oncology Startups Portfolio.***

## **Section C : Individual Immuno Oncology Startup Profile (with Active Pipeline)**

**69**

- ***A to Z Alphabetical Profiles of Active ImmunoOncology Startups (Top 400 Companies)***

Individual Company Profile Covers: An Overview to Drug Developer, Key technology platform, Venture Funding Rounds, Oncology centered Deals & Partnership, Collaborations and Business Insights.

**ImmunoOncology Drug Pipeline** –Drugs name, its targets, with details of its development for various indications for cancer cure.

**Management Profile** –Address, Contact number, e-mail, Key Management / Decision Maker (CXOs) name and designation, with individual Linked ID and contact emails.

***Appendix A: Index - Country Wise List of 400 ImmunoOncology Startups.....*** **331**

***Appendix B: Index - ImmunoOncology Molecules in Clinical/Preclinical Development, along with their Developer's Name.....*** **334**

## LIST OF FIGURES

<b>Section A : ImmunoOncology Startups - Infographics</b>		<b>15</b>
<b>Figure A.1</b>	Qualitative Estimation of Top 400 Active ImmunoOncology Startups, present in <b>U.S.A vs. Europe vs. Asia vs. Rest of the World</b> . (Established between 2010 to 2019)	<b>16</b>
<b>Figure A.2</b>	Bar Graph for year specific establishment of Top 400 Active ImmunoOncology Startups. (Established between 2010 to 2019)	<b>16</b>
<b>Figure A.3</b>	Individual Country specific Distribution of ImmunoOncology Startups (Drug Developer) in EuroAsia Region - <b>Europe</b> (110 Countries) and in <b>Asia</b> (63 Countries).	<b>17</b>
<b>Figure A.4</b>	<b>U.S State</b> specific Distribution of ImmunoOncology Startups in <b>U.S.A.</b> (210 Countries). (Established between 2010 to 2019).	<b>17</b>

## LIST OF TABLES

<b>Section A &amp; B: ImmunoOncology Startups - Intelligence</b>		<b>18</b>
<b>Table A.1</b>	Top 15 <b>Highly Innovative Startups</b> capable of changing future of ImmunoOncology Drug Discovery & Development.	<b>18</b>
<b>Table A.2</b>	<b>Immune Checkpoint Modulator</b> focused Drug Developers, established between 2010 to mid of 2019. (43 Companies)	<b>20</b>
<b>Table A.3</b>	<b>Cellular Immunotherapies</b> developing ImmunoOncology StartUps, established between 2010 to mid 2019. (98 Companies)	<b>22</b>
<b>Table A.4</b>	<b>Oncolytic Viruses based Therapies</b> developing ImmunoOncology StartUps, established between 2010 to mid 2019. (33 Companies)	<b>26</b>
<b>Table A.5</b>	<b>Peptide Vaccine</b> developing ImmunoOncology StartUps, established between 2010 to mid 2019. (27 Companies)	<b>28</b>
<b>Table A.6</b>	<b>Bispecific T Cell Engagers</b> developing ImmunoOncology StartUps, established between 2010 to mid 2019. (13 Companies)	<b>30</b>
<b>Table A.7</b>	<b>Monoclonal Antibodies against Tumor Antigens</b> developing ImmunoOncology StartUps, established between 2010 to mid 2019. (93 Companies)	<b>31</b>
<b>Table B.1</b>	ImmunoOncology Startups <b>MAJOR DEALS &amp; PARTNERING ACTIVITIES - 2019. (uptill Nov. 2019)</b>	<b>34</b>
<b>Table B.2</b>	ImmunoOncology Startups <b>MAJOR DEALS &amp; PARTNERING ACTIVITIES - 2018.</b>	<b>38</b>
<b>Table B.3</b>	ImmunoOncology Startups <b>MAJOR DEALS &amp; PARTNERING ACTIVITIES - 2017.</b>	<b>44</b>
<b>Table B.4</b>	ImmunoOncology Startups <b>Funding- 2019. (uptill Nov. 2019)</b>	<b>49</b>
<b>Table B.5</b>	ImmunoOncology Startups <b>Funding- 2018.</b>	<b>52</b>
<b>Table B.6</b>	ImmunoOncology Startups <b>Funding- 2017.</b>	<b>58</b>
<b>Table B.7</b>	<b>BIG PHARMA Investment Portfolio &amp; Research Partnering</b> with ImmunoOncology Drug Development Startups.	<b>62</b>
<b>Table B.8</b>	<b>Top 10 Venture Investors</b> in ImmunoOncology Startups & Their Investment Portfolio.	<b>63</b>